Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Generic Name
- Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Brand Names
- Trumenba
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 583WCD0IZI
- Background
Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).
- Associated Conditions
- Infection caused by Neisseria Meningitidis Serogroup B
GSK's Penmenvy Approved by FDA for Meningococcal Disease Prevention in Adolescents and Young Adults
• The FDA has approved GSK's Penmenvy vaccine for individuals aged 10-25, targeting five major serogroups of Neisseria meningitidis.
• Penmenvy combines antigenic components from GSK's Bexsero and Menveo vaccines, offering broader protection against invasive meningococcal disease (IMD).
• Clinical trials demonstrated a safety profile consistent with GSK's existing meningococcal vaccines, showing effective immune responses.
• The CDC's Advisory Committee on Immunization Practices will vote on recommendations for Penmenvy's use in adolescents and young adults.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath